|
|
|
| Preparation and Characterization of Platelet Membrane Biomimetic Nanocarriers and Transplacental Barrier Transport Efficiency in vitro |
| Hu Danhui1, Pan Yuxue1, Wang Peng1, Jiao Zhenna1, Wan Guoyun1,2, Wang Haijiao1,2, Sui Junhui1,2, Tang Hongbo3, Chen Hongli1,2#* |
1(The Key Laboratory of Biomedical Material, School of Life Science and Technology, Xinxiang Medical University, Xinxiang 453003, Henan, China)
2(The Third Affiliated Hospital of Xinxiang Medical University,Xinxiang 453003, Henan, China)
3(Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China) |
|
|
|
|
Abstract This study aims to construct a platelet membrane biomimetic nanocarrier and evaluate the transport efficiency across the placental cell barrier in vitro. The poly(lactic-co-glycolic acid) nanoparticles coated with platelet membrane (P-PLGA NPs) were fabricated by different approach including sonication, coextrusion and covalent connection. The physicochemical characteristics of the P-PLGA NPs were investigated by particle size analyzer, TEM, SDS-PAGE and Elisa, by which the optimal preparation method was determined. Cytotoxicity of the nanocarriers to the cell line BeWo b30 were evaluated by MTT assay. The influence of different endocytic inhibitors on the cellular uptake was examined using flow cytometry. The transwell device was used to investigate the transplacental barrier efficiency of the nanocarriers in vitro. Results showed that the size of P-PLGA NPs prepared by sonication, physical extrusion and covalention was (269.1±32.9), (425.0±36.6), and (823.4±73.1) nm, respectively, which were higher than PLGA NPs, and the value of zeta potential was close to the platelet membrane. The surface membrane proteins were intact and specific protein marker P-selectin still present. The cell viability in all groups had no significant difference compared with the control group (P>0.05). Compared with the control group, the cellular uptake inhibition of NY was 53% in the PLGA NPs group and that of AMR was 45% in P-PLGA NPs group, and the uptake pathway was caveolin-mediated endocytosis and macropinocytosis. In the placental cell barrier model, the PLGA NPs transport efficiency was 6% and 24.3% higher at apical chamber administration concentrations of 5 and 20 μg/mL, respectively, and the P-PLGA NPs transport efficiency was PLGA NPs 13.8% higher at 100 μg/mL. The PLGA NPs transport efficiency was 6% and 24.3% higher than P-PLGA NPs at apical chamber administration concentrations of 5 and 20 μg/mL, respectively, and the P-PLGA NPs transport efficiency was 13.8% higher than PLGA NPs at 100 μg/mL. In conclusion, the platelet membrane was successfully coated on the surface of PLGA NPs. The P-PLGA NPs prepared by sonication had a smaller size and better size distribution. When the nanocarriers' concentration was increased, P-PLGA NPs showed significant increasing transport efficiency in the placental barrier.
|
|
Received: 30 May 2022
|
|
|
|
Corresponding Authors:
* E-mail: chenhlhl@126.com
|
| About author:: # Member, Chinese Society of Biomedical Engineering |
|
|
|
[1] Wang Shuyan, Duan Yaou, Zhang Qianzhe, et al. Drug targeting via platelet membrane-coated nanoparticles [J]. Small Struct, 2020, 1(1): 2000018.
[2] Kunde SS, Wairkar S. Platelet membrane camouflaged nanoparticles: Biomimetic architecture for targeted therapy [J]. Int J Pharmaceut, 2021, 598: 120395.
[3] Lazar S, Goldfinger LE. Platelets and extracellular vesicles and their cross talk with cancer [J]. Blood, 2021, 137(23): 3192-3200.
[4] Smeda M, Przyborowski K, Stojak M, et al. The endothelial barrier and cancer metastasis: Does the protective facet of platelet function matter? [J]. Biochem Pharmacol, 2020, 176: 113886.
[5] Dib PRB, Quirino-Teixeira AC, Merij LB, et al. Innate immune receptors in platelets and platelet-leukocyte interactions [J]. J Leukocyte Biol, 2020, 108(4): 1157-1182.
[6] Rayes J, Bourne JH, Brill A, et al. The dual role of platelet-innate immune cell interactions in thrombo-inflammation [J]. Res Pract Thromb Hae, 2019, 4(1): 23-35.
[7] Khodadi E. Platelet function in cardiovascular disease: activation of molecules and activation by molecules [J]. Cardiovasc Toxicol, 2020, 20(1): 1-10.
[8] Han Huijie, Bártolo R, Li Jiachen, et al. Biomimetic platelet membrane-coated nanoparticles for targeted therapy [J]. Eur J Pharm Biopharm, 2022, 172: 1-15.
[9] Unterberger U, Eichelberger B, Ulz A, et al. Antibodies against complement-regulatory proteins on platelets in immune thrombocytopenia [J]. Platelets, 2017, 28(4): 409-413.
[10] Guido C, Maiorano G, Cortese B, et al. Biomimetic nanocarriers for cancer target therapy [J]. Bioengineering, 2020, 7(3): 111-126.
[11] Wang Haijun, Wu Junzi, Williams GR, et al. Platelet-membrane-biomimetic nanoparticles for targeted antitumor drug delivery [J]. J Nanobiotechnol, 2019, 17(1): 60-76.
[12] 李爽, 程波, 王强, 等. 血小板与内皮细胞屏障功能 [J]. 中华危重症医学杂志, 2019, 12(1): 56-60.
[13] Jiang Qin, Wang Kuang, Zhang Xingyu, et al. Platelet membrane-camouflaged magnetic nanoparticles for ferroptosis-enhanced cancer immunotherapy [J]. Small, 2020,16(22): 2001704.
[14] Zheng Wanshan, Hu Xiaoqian, Wang Yanling, et al. Mechanisms for establishment of the placental defensive barrier [J]. Acta Physiologica Sinica, 2020, 72(1): 115-124.
[15] Figueroa-Espada CG, Hofbauer S, Mitchell MJ, et al. Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy [J]. Adv Drug Deliver Rev, 2020, 160: 244-261.
[16] Cooke LDF, Tumbarello DA, Harvey NC, et al. Endocytosis in the placenta: an undervalued mediator of placental transfer [J]. Placenta, 2021, 113: 67-73.
[17] 郭洁, 宋殿荣. BeWo细胞模型及其在胎盘转运机制研究中的应用 [J]. 中国中药杂志, 2012, 37(21): 3193-3197.
[18] Abdelkhaliq A, van der Zande M, Peters R, et al. Combination of the BeWo b30 placental transport model and the embryonic stem cell test to assess the potential developmental toxicity of silver nanoparticles [J]. Part Fibre Toxicol, 2020, 17(1): 11-27.
[19] Tang Hongbo, Jiang Ziwen, He Haibo, et al. Uptake and transport of pullulan acetate nanoparticles in the BeWo b30 placental barrier cell model [J]. Int J Nanomedicine, 2018, 13: 4073-4082.
[20] Jiang Ziwen, Tang Hongbo, Xiong Qingqing, et al. Placental cell translocation of folate-conjugated pullulan acetate non-spherical nanoparticles [J]. Colloids Surf B Biointerfaces, 2022, 216: 112553.
[21] Hara K, Tsujimoto H, Huang CC, et al. Ultrastructural and immunohistochemical studies on uptake and distribution of FITC-conjugated PLGA nanoparticles administered intratracheally in rats[J]. J Toxicol Pathol, 2012, 25(1): 19-26.
[22] Lee NH, You Sumin, Taghizadeh A, et al. Cell membrane-cloaked nanotherapeutics for targeted drug delivery [J]. Int J Mol Sci, 2022, 23(4): 2223-2245.
[23] Zhu Li, Zhong Yuan, Wu Shuai, et al. Cell membrane camouflaged biomimetic nanoparticles: Focusing on tumor theranostics [J]. Mater Today Bio, 2022, 14:100228.
[24] Yu Biao, Xue Xu, Yin Zhifeng, et al. Engineered cell membrane-derived nanocarriers: The enhanced delivery system for therapeutic applications [J]. Front Cell Dev Biol, 2022, 10: 844050.
[25] Hu CMJ, Fang RH, Wang Kueichun, et al. Nanoparticle biointerfacing by platelet membrane cloaking [J]. Nature, 2015, 526(7571): 118-121.
[26] Secor D, Swarbreck S, Ellis CG, et al. Ascorbate inhibits platelet-endothelial adhesion in an in-vitro model of sepsis via reduced endothelial surface P-selectin expression [J]. Blood Coagul Fibrinolysis, 2017, 28(1): 28-33.
[27] Van der Poll T, Parker RI. Platelet activation and endothelial cell dysfunction [J]. Crit Care Clin, 2020, 36(2): 233-253.
[28] Miyazawa B, Trivedi A, Togarrati PP, et al. Regulation of endothelial cell permeability by platelet-derived extracellular vesicles [J]. J Trauma Acute Care, 2019, 86(6): 931-942.
[29] Winneberger J, Schöls S, Lessmann K, et al. Platelet endothelial cell adhesion molecule-1 is a gatekeeper of neutrophil transendothelial migration in ischemic stroke [J]. Brain Behav Immun, 2021, 93: 277-287. |
|
|
|
